ANN ARBOR, Mich., May 14, 2012 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic
DNA-based therapeutics and innovative disease-modifying medicines
for serious illnesses, announced today the appointment of
Carol Reed, M.D., as Senior Vice
President of Clinical & Regulatory Affairs. In this position,
Dr. Reed will be responsible for the design and implementation of
all aspects of clinical development, including clinical trials, and
will lead the Company's regulatory initiatives. Dr. Reed brings
over 25 years of experience, in medical practice and in the
biotechnology/pharmaceutical sector, including six years with
Clinical Data, Inc., a publicly-traded biopharmaceutical company
which was acquired by Forest Laboratories, Inc.
Most recently, Dr. Reed served as Chief Medical Officer at
Clinical Data, Inc. from 2005 through 2011, after the company
merged with Genaissance Pharmaceuticals, Inc., where she had served
as Vice President, Medical Affairs since 2003. During her tenure at
Clinical Data, Inc., Dr. Reed was responsible for the design and
management of two successful consecutive Phase III clinical trials
for VIIBRYD® which is used in the treatment of major depressive
disorder in adults. These efforts led to the approval of VIIBRYD in
January 2011 by the U.S. Food and
Drug Administration. Prior to this time, Dr. Reed served as
Associate Medical Director in Pulmonary Medical Research at Bayer
Pharmaceuticals, Inc. Previously, she was the Associate Director,
Section of Pulmonary and Critical Care Medicine at the Hospital of
St. Raphael and directed its Medical Intensive Care Unit.
"We are very pleased to add an executive of Carol's caliber to
the Synthetic Biologics' team. Carol's broad experience in clinical
development, as well as her leadership skills, are expected to be
tremendous assets to the Company as we continue to work to build
our development pipeline and move our ongoing MS and ALS clinical
programs forward," stated Jeffrey
Riley, Chief Executive Officer at Synthetic Biologics.
Dr. Reed earned an M.D. from the Rush Medical College in
Chicago and an M.S. in Biology
from the University of Illinois.
About Synthetic Biologics, Inc.
Synthetic Biologics is a biotechnology company focused on the
development of synthetic DNA-based therapeutics and innovative
disease-modifying medicines for serious illnesses. Synthetic
Biologics is developing, or has partnered the development of,
product candidates for the treatment of pulmonary arterial
hypertension (PAH), relapsing-remitting multiple sclerosis (MS),
cognitive dysfunction in MS, fibromyalgia and amyotrophic lateral
sclerosis (ALS). For more information, please visit Synthetic
Biologics' website at www.syntheticbiologics.com.
This release includes forward-looking statements on Synthetic
Biologics' current expectations and projections about future
events. In some cases forward-looking statements can be identified
by terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions. These statements are based
upon current beliefs, expectations and assumptions and are subject
to a number of risks and uncertainties, many of which are difficult
to predict and include statements regarding our continued
development pipeline, our intent to move our clinical
programs forward and the expected contribution of Dr Reed. The
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from those set
forth or implied by any forward-looking statements. Important
factors that could cause actual results to differ materially from
those reflected in Synthetic Biologics' forward-looking statements
include, among others, a failure to successfully integrate the new
management and other factors described in Synthetic Biologics'
report on Form 10-K for the year ended December 31, 2011 and any other filings with the
SEC. The information in this release is provided only as of the
date of this release, and Synthetic Biologics undertakes no
obligation to update any forward-looking statements contained in
this release on account of new information, future events, or
otherwise, except as required by law.
VIIBRYD® is a registered copyright of Forest Laboratories,
Inc.
SOURCE Synthetic Biologics, Inc.